[go: up one dir, main page]

MX2009006243A - Potenciadores del receptor ampa. - Google Patents

Potenciadores del receptor ampa.

Info

Publication number
MX2009006243A
MX2009006243A MX2009006243A MX2009006243A MX2009006243A MX 2009006243 A MX2009006243 A MX 2009006243A MX 2009006243 A MX2009006243 A MX 2009006243A MX 2009006243 A MX2009006243 A MX 2009006243A MX 2009006243 A MX2009006243 A MX 2009006243A
Authority
MX
Mexico
Prior art keywords
ampa receptor
receptor potentiators
potentiators
psychiatric
useful
Prior art date
Application number
MX2009006243A
Other languages
English (en)
Inventor
Esteban Dominguez-Manzanares
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2009006243A publication Critical patent/MX2009006243A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto de la Fórmula (I) o una sal farmacéuticamente aceptable del mismo, el cual es útil para el tratamiento de condiciones asociadas con hipofunción de glutamato, tales como trastornos psiquiátricos y neurológicos.
MX2009006243A 2006-12-11 2007-12-06 Potenciadores del receptor ampa. MX2009006243A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06380319 2006-12-11
US88856207P 2007-02-07 2007-02-07
PCT/US2007/086567 WO2008073789A1 (en) 2006-12-11 2007-12-06 Ampa receptor potentiators

Publications (1)

Publication Number Publication Date
MX2009006243A true MX2009006243A (es) 2009-08-12

Family

ID=39272878

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006243A MX2009006243A (es) 2006-12-11 2007-12-06 Potenciadores del receptor ampa.

Country Status (10)

Country Link
US (1) US8097652B2 (es)
EP (1) EP2102153A1 (es)
JP (1) JP2010512339A (es)
KR (1) KR20090082278A (es)
CN (1) CN101541741A (es)
AU (1) AU2007333247B2 (es)
CA (1) CA2672462A1 (es)
EA (1) EA015600B1 (es)
MX (1) MX2009006243A (es)
WO (1) WO2008073789A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180326B (zh) 2010-08-10 2015-06-10 武田药品工业株式会社 杂环化合物及其用途
JP5976011B2 (ja) 2011-04-05 2016-08-23 武田薬品工業株式会社 スルホンアミド誘導体およびその用途
JP7085242B2 (ja) * 2017-12-21 2022-06-16 深▲チェン▼市塔吉瑞生物医薬有限公司 キナーゼ活性を阻害するためのアリールホスフィンオキシド
JOP20220063A1 (ar) 2019-09-16 2023-01-30 Takeda Pharmaceuticals Co مشتقات بيريدازين-3(2h)-أون ملتحمة بأزول

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
HRP20020918A2 (en) * 2000-05-19 2004-02-29 Lilly Co Eli Sulfonamide derivatives

Also Published As

Publication number Publication date
KR20090082278A (ko) 2009-07-29
EA015600B1 (ru) 2011-10-31
US8097652B2 (en) 2012-01-17
US20100010090A1 (en) 2010-01-14
EA200970573A1 (ru) 2009-10-30
WO2008073789A1 (en) 2008-06-19
EP2102153A1 (en) 2009-09-23
AU2007333247A1 (en) 2008-06-19
AU2007333247B2 (en) 2012-06-07
CA2672462A1 (en) 2008-06-19
JP2010512339A (ja) 2010-04-22
CN101541741A (zh) 2009-09-23

Similar Documents

Publication Publication Date Title
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
TW200728307A (en) Novel spirochromanone derivatives
NO20070249L (no) Pyrrazolo-pyrimidin derivater
WO2007104783A3 (en) 1,4 -di substituted 3-cyano-pyridone derivatives and their use as positive mglur2-recept0r modulators
WO2007078523A3 (en) 5-phenyl-3-benzyl-0xaz0lidin-2-0ne derivatives and related compounds as metabotropic glutamate receptor potentiators for the treatment of neurological and psychiatric disorders
MX2009005252A (es) Aminopirrolidinas como antagonistas del receptor de quimiocina.
GB0510141D0 (en) Novel compounds B3
UA87856C2 (ru) Алкильные производные как модуляторы метаботропных рецепторов глутамата
WO2009140166A3 (en) Oxazolobenzimidazole derivatives
UA106873C2 (uk) Сполуки заміщених діазепанів як антагоністи орексинових рецепторів
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
MX2007004794A (es) Tienopiridinas como potenciadores alostericos del receptor muscarinico m4.
IL194057A0 (en) Pyrimidine, quinazoline, pteridine and triazine derivatives
MX2009006359A (es) Derivados de aril sulfamida y metodos para su uso.
TW200621739A (en) Asymmetric synthesis of substituted dihydrobenzofurans
WO2008131946A3 (de) Substituierte amid-derivate
WO2006123255A3 (en) Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
NO20055465L (no) Imidazolderivater som glutamatreseptorantagonister
AU2001274806A1 (en) Sulfonamide derivatives
MX2009006243A (es) Potenciadores del receptor ampa.
GB0513886D0 (en) Novel compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal